Continuous infusion of meropenem in critically ill patients: practical considerations

Critical Care

Volumn 16, Issue 4, 2012, Pages

  Taccone, Fabio S ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; ERADICATION THERAPY; LETTER; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SEPSIS; SEPTIC SHOCK; VENTILATOR ASSOCIATED PNEUMONIA; CRITICAL ILLNESS; FEMALE; HUMAN; INTENSIVE CARE UNIT; MALE; TRENDS;

ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; THIENAMYCINS;

EID: 84865998994     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11459     Document Type: Letter

References (11)

1. Chytra I, Stepan M, Benes J, Pelnar P, Zidkova A, Bergerova T, Pradl R, Kasal E. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care 2012, 16:R113. 10.1186/cc11405, 22742765.
2. Lorente L, Jiménez A, Palmero S, Jiménez JJ, Iribarren JL, Santana M, Martín MM, Mora ML. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review. Clin Ther 2007, 29:2433-2439. 10.1016/j.clinthera.2007.11.003, 18158083.
3. Mohd Hafiz AA, Staatz CE, Kirkpatrick CM, Lipman J, Roberts JA. Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics. Minerva Anestesiol 2012, 78:94-104.
4. Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010, 14:R126. 10.1186/cc9091, 2945087, 20594297.
5. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009, 64:142-150. 10.1093/jac/dkp139, 19398460.
6. Novelli A, Fallani S, Cassetta MI, Conti S, Mazzei T. Postantibiotic leukocyte enhancement of meropenem against Gram-positive and Gram-negative strains. Antimicrob Agents Chemother 2000, 44:3174-3176. 10.1128/AAC.44.11.3174-3176.2000, 101625, 11036045.
7. Georges B, Conil JM, Cougot P, Decun JF, Archambaud M, Seguin T, Chabanon G, Virenque C, Houin G, Saivin S. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. Int J Clin Pharmacol Ther 2005, 43:360-369.
8. Ludwig E, Konkoly-Thege M, Kuti JL, Nicolau DP. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals. Int J Antimicrob Agents 2006, 28:433-438. 10.1016/j.ijantimicag.2006.07.014, 17046212.
9. Wang H, Zhang B, Ni Y, Kuti JL, Chen B, Chen M, Nicolau DP. Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004. Int J Antimicrob Agents 2007, 30:452-457. 10.1016/j.ijantimicag.2007.06.005, 17646088.
10. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998, 27:10-22. 10.1086/514622, 9675443.
11. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008, 31:345-351. 10.1016/j.ijantimicag.2007.12.009, 18313273.